A Merck official says the recommendation by a federal health committee that those 60 and older get shingles vaccinations should open doors for the use of Merck's Zostavax vaccine. The endorsement is likely to increase the number of health plans that offer insurance coverage for the vaccine, he said.

Full Story:

Related Summaries